Premium
Oestrogen Pre‐treatment Abolishes Luteinising Hormone‐Releasing Hormone Testosterone Stimulation
Author(s) -
KREIS W.,
AHMANN F. R.,
JORDAN V. C.,
HAAN H.,
SCOTT M.
Publication year - 1988
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1988.tb04364.x
Subject(s) - testosterone (patch) , medicine , buserelin , hormone , endocrinology , prostate cancer , stimulation , agonist , prostate , priming (agriculture) , cancer , biology , receptor , botany , germination
Summary— In patients with histologically confirmed prostate cancer, oestrogen priming with diethylstilboestrol (DES) (3 mg/day) for 4 weeks prior to the first injection of the LHRH agonist Zoladex (3.6 mg depot form) prevented any rise in the serum testosterone concentration. In contrast, in the groups pre‐treated with DES, the first, but not subsequent, injections with Zoladex were associated with a marked surge in luteinising hormone. Treatment with DES beyond the time of the first administration of Zoladex did not provide further endocrinological advantage. Oestrogen priming for 1 month prior to treatment with Zoladex may prevent an exacerbation of signs and symptoms of prostate cancer.